THERAVANCE INC (THRX)
(Delayed Data from NSDQ)
$9.81 USD
+0.04 (0.41%)
Updated Jan 8, 2016 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[THRX]
Reports for Purchase
Showing records 1 - 20 ( 91 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Platform Foundation Remains Strong, Despite THE-630 GIST Discontinuation; Reit Buy and $9PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Theseus Discontinues THE-630 in GIST Citing DLTs; Reit. Buy and Lowering Our PT to $9 from $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Positive Clinical Data for THE-630, Points to a Formidable Pan-KITi for GIST
Provider: H.C. Wainwright & Co., Inc.
Analyst: FYHR M
Industry: Medical - Biomedical and Genetics
HEALTHCARE- The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
All Eyes on Initial THE-630 Dose Escalation Data During ASCO ?23; Reit. Buy and $22 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Theseus vs. GIST 1st Round Results Around the Corner
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Positive Ahead of THE-630 Update in 2Q23; Reit. Buy and $22 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A